Edition:
United States

CytRx Corp (CYTR.A)

CYTR.A on American Stock Exchange

2.75USD
22 Sep 2015
Change (% chg)

-- (--)
Prev Close
$2.75
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
--
52-wk Low
--

Select another date:

Tue, Nov 29 2016

BRIEF-Cytrx reports statistically significant updated results from pivotal phase 3 trial of aldoxorubicin in patients with second-line soft tissue sarcomas

* Cytrx-Reports statistically significant updated results from pivotal phase 3 trial of aldoxorubicin in patients with second-line soft tissue sarcomas

BRIEF-Cytrx presents positive interim results from on-going clinical trial

* Cytrx says dose-limiting toxicities were not observed in either cohort, and no clinically significant cardiac toxicities were seen

BRIEF-Cytrx Q3 loss $0.13/shr

* Cytrx Corp - during Q3, embarked on a plan to reduce spending until additional results from Aldoxorubicin phase 3 STS clinical trial are available

BRIEF-Cytrx completes enrollment in lung cancer mid-stage study

* Says Completion Of Enrollment In Its Global Phase 2b Clinical Trial Of Aldoxorubicin In Patients With Second Line small cell lung cancer

BRIEF-Cytrx reports loss per share of $0.27 for Q2 2016

* Q2 loss per share $0.27 Source text for Eikon: Further company coverage:

BRIEF-CVI Investments reports 7.5 pct passive stake in Cytrx as of July 15

* CVI Investments reports 7.5 pct passive stake in Cytrx as of July 15 - SEC filing Source text (http://bit.ly/2aAKZQa) Further company coverage: (Bengaluru Newsroom : +1-646-223-8780)

BRIEF-Cytrx Corp announces pricing of $20 mln public offering

* Cytrx Corp announces pricing of $20 million public offering of common stock and warrants

BRIEF-CytRx reports initial results of aldoxorubicin late-stage trial in soft tissue sarcoma patients

July 11 Cytrx Announces Initial Results Of Phase 3 Trial Of Aldoxorubicin In Patients With Second

Select another date: